Madison Doctor Warns GLP-1 Boom Outpaces 21 Years of Science
Updated
Updated · The Capital Times · Jul 10
Madison Doctor Warns GLP-1 Boom Outpaces 21 Years of Science
2 articles · Updated · The Capital Times · Jul 10
Summary
Dr. David Harris of UW-Madison said surging demand for Ozempic, Wegovy and Zepbound is moving faster than evidence on long-term effects, ideal treatment length and which patients benefit most.
High prices and intermittent shortages are pushing some patients toward compounded or gray-market drugs sold online or through med spas, raising concerns about product quality, dosing and safety.
Harris said GLP-1s can be highly effective for obesity when medically supervised, but some patients do not respond and weight regain after stopping treatment is "pretty much universal," often making them lifelong medicines.
FDA approvals have expanded from diabetes treatment in 2005 to weight-loss drugs such as Wegovy in 2021 and Zepbound in 2023, but Harris said the medications are not one-size-fits-all and should be paired with lifestyle changes.
Access remains a major constraint: Harris said multidisciplinary care is safest, yet many patients cannot afford approved drugs and turn to riskier alternatives in a fragmented U.S. healthcare system.
New drugs promise surgery-like weight loss. Are we ignoring the unknown, long-term health risks that could follow?
Stopping weight-loss drugs means regaining fat, not muscle. Is this creating a lifelong dependency trap for millions of users?
With black-market drugs surging, are patients being forced to gamble with their health due to the high cost of approved medications?
The Great American GLP-1 Experiment: Benefits, Risks, and the Future of Metabolic Health in 2026
Overview
The report highlights a dramatic rise in the use of GLP-1 receptor agonist drugs for metabolic health, marking a major shift in weight management and chronic disease care. Public acceptance is growing, with over a quarter of surveyed Americans viewing these drugs as a valid option, and stigma around their use is fading. This surge is driven by both medical need and changing attitudes, but it brings new challenges, such as drug interactions and the need for careful patient monitoring. The rapid adoption of GLP-1s signals a new era in healthcare, requiring updated guidelines and strong oversight to ensure safety and effectiveness.